Abstract: A composition of matter comprises a shelf stable, super critical, CO2 fluid extracted seed oil derived from a cracked biomass of perilla frutescens, the seed oil comprising from about 60 to about 95 percent w/w of PUFAs in a ratio of from about 4:1 to about 6:1 alpha-linolenic acid (ALA) to linoleic acid (LA) and a mixture of selected antioxidants.

Abstract: The present invention is directed to transdermal compositions and the uses thereof. These compositions include at least one of the following components: a C1-C6 dialkyl, C12-C30 dialkyl quaternary ammonium salt, a C12-C30 fatty acid, a nitrogenous organic base, C12-30 fatty alcohol, monoglyceride or the reaction products thereof.

Abstract: The invention describes methods and agents for improving cosmetic appearance, for promoting, improving or restoring health of cells and tissues, preferably skin, and more preferably, for restoring aged or damaged skin to a healthy appearance. In some embodiments, the invention relates to compositions of cells, eggs, cell extracts, egg extracts, and extract components such as purified nucleic acids, polypeptides, lipids, carbohydrates or other natural products.

Abstract: Methods, compositions, and strategies for the treatment of malignant neoplasms are presented herein. The treatment modalities are directed towards exploiting characteristics of cancer cells as well as correcting defective biochemical pathways and systems in the body.

Abstract: The present invention relates to a composition for reducing the tendency of an animal to enter sexual maturation, reducing or preventing oxidative damage in an animal, for reducing or preventing oxidative stress in an animal, promoting growth of an animal and for avoiding enlarged liver size in fish. The present invention also relates to a composition having improved characteristics with regard to the stability of easily oxidised components during production and storage; and with regard to the utilization of the easily oxidised components.

Abstract: The present invention relates to a nutritional composition for infants and/or toddlers comprising a lipid component which has a large lipid globule size, having a volume weighted mode diameter above 1.0 ?m and/or with a diameter of 2 to 12 ?m in a amount of at least 45 volume % based on total lipid. The composition can be used to increase bone mineral content and/or bone mass density, to prevent osteoporosis and/or osteopenia and for the further prevention of obesity.

Abstract: The present invention relates to a nutritional composition for infants and/or toddlers comprising a lipid component which has a lipid globules coated with phospholipids. The composition is used for increasing bone mineral content, bone mineral density, preventing osteoporosis, and/or preventing ostopenia.

Abstract: A Salvia hispanica L. derived seed oil extract composition of matter containing from 60-88% PUFAS in a ratio of from 3.1:1-3.3:1 of ALA to LA, 4-10% of C-18 mono-unsaturated fatty acid, 1-5% of C-18 saturated fatty acid and 4-8% of C-16 saturated fatty acid in a mixed triglyceride form stable at room temperature of 12-24 months containing a mixture of selected antioxidants.

Abstract: Disclosed herein is a lipid preparation, said preparation comprising a phosphatidylserine moiety, and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. Said lipid preparations are particularly useful in the treatment of mental and cognitive disorders, e.g. ADHD (attention deficit hyperactivity disorder) and Alzheimer's disease. The disclosed preparations present improved bioactivity, and are useful in the treatment of various cognitive and mental conditions and disorders, as well as for maintenance of normal functions of brain-related systems and processes.

Abstract: A composition and method which improves blood lipid profiles and optionally reduces low density lipoprotein (LDL) per-oxidation in humans by administering a therapeutic amount of a composition comprising krill oil in combination with astaxanthin or a mixture of fish oil derived, choline based, phospholipid bound omega-3 fatty acid mixture including phospholipid bound polyunsaturated EPA and DHA. In one embodiment, the krill oil is derived from Euphasia spp., comprising Eicosapentaenoic (EPA) and Docosahexaenoic (DHA) fatty acids in the form of triacylglycerides and phospholipids. The krill oil includes at least 10% EPA and 5% DHA, of which greater than 50% are in the form of phospholipids and the 1-4000 mg of krill oil per daily dose is delivered.

Abstract: A method for treating a skin ailment by applying a personal composition from a collapsible dispenser. The collapsible dispenser includes a collapsible bag at least partially surrounded by an elastically deformable member and, optionally, an outer container body. Potential energy is generated by stretching the elastically deformable member, which is used to dispense the composition in lieu of a propellant or pump. The personal care composition may be a skin care composition, an antifungal, or an enzyme inhibiting composition.

Abstract: This invention relates to a combination product or medicament comprising at least one novel substituted pyrrole derivative and one or more dyslipidemic agents, antiobesity agents, antihyperglycaemic agents, anti-inflammatory agents or mixture thereof.

Abstract: The invention provides an oral nutraceutical or pharmaceutical composition comprising at least one polyunsaturated fatty acid (PUFA) or a derivative thereof for use in treating defects of vision, e.g. long-sightedness (hyperopia). In some embodiments, the PUFA in the composition is provided by an oil purified from squid.

Abstract: The present invention relates to compositions suitable for improving oxidative stability of marine oils, marine oils having improved oxidative stability as well as methods for manufacturing such compositions.

Abstract: Compositions containing the fatty acid docosahexaenoic acid (DHA) in combination with at least one vitamin and mineral are provided to supplement nutrition in a mammalian diet. DHA is present in the composition in concentrated amounts, advantageously in a carrier such as marinol oil, to allow for quantities of DHA sufficient to supply expectant and new mothers and their children as recommended on a daily basis. This DHA may also be used to treat a variety of disorders in children and adults. The compositions advantageously include vitamins, minerals, and optionally other nutrients to provide a nutritional supplement which may be convenient to swallow and taken once a day.

Abstract: The present invention relates to a nutritional composition for infants and/or toddlers comprising a lipid component which has a large lipid globule size. The composition can be used to prevent obesity and/or improve body composition later in life. Said lipid component comprises 10-50 wt % vegetable lipids, and the lipid globules have a volume-weighted diameter above 1.0 m and/or a diameter of 2-12 m in an amount of at least 45 vol %.

Abstract: The present invention provides a proprietary compositions and systems to modulate genetic and metabolomic contributing factors affecting disease diagnosis, stratification, and prognosis, as well as the metabolism, efficacy and/or toxicity associated with specific vitamins, minerals, herbal supplements, homeopathic ingredients, and other ingredients for the purposes of customizing a subject's nutritional supplement formulation to optimize specific health outcomes. Specific to this invention the utilization of certain known polymorphic genes associated with Substance Use Disorder (SUD) are analyzed to target certain genetic anomalies that lead to a high risk and predisposition to SUD. The genotypic patterns are then utilized to provide certain nutritional customized solutions especially related to the attenuation of aberrant abuse of physician prescribed narcotic pain medication across all pain conditions.

Abstract: A clear soft vegetarian dosage capsule comprising a first and second biphasic film. The first biphasic film has a plurality of first reservoirs and further comprises a polysaccharide, a seaweed extract, a rheology modifier, a buffer and a plasticizer. The second biphasic film has a plurality of second reservoirs having a formulation identical to the first film to ensure a sealing engagement. A dosage amount is disposed in each of the plurality of the reservoirs forming a plurality of filled reservoirs. The dosage amount is an emulsion, oil, hydrophilic liquid. The first film is extruded or overlaid with the second film allowing each of the plurality of second reservoirs to overlay the filled reservoirs and sealed with pressure and a fusion temperature slightly less than the melting point of the first and second films forming clear soft vegetarian dosage capsules that are blown dry, bonding moisture to the polysaccharide.

Abstract: Methods and compositions containing a berberine compound or berberine related or derivative compound are provided for the prevention and treatment of hyperlipidemia, elevated cholesterol, and/or cardiovascular disease in mammalian subjects. The methods and compositions of the invention are effective for prevention and treatment of atherosclerosis, coronary artery disease, angina pectoris, carotid artery disease, stroke, cerebral arteriosclerosis, high blood pressure, myocardial infarction, cerebral infarction, restenosis following balloon angioplasty, intermittent claudication, dyslipidemia post-prandial lipidemia or xanthoma.

Abstract: A lipid preparation including a glycerophospholipid or salt, conjugate and derivatives thereof, particularly phosphatidylserine (PS), phosphatidyicholine (PC), phosphatidylethanolamine (PE), phosphatidyl-inositol (PI), phosphatidylglycerol (PG) and phosphatidic acid (PA), and poly-unsaturated fatty acid (PUFA) acyl groups, particularly long-chain poly-unsaturated fatty acid (LC-PUFA) acyl groups such as omega-3 and/or omega-6 acyl groups, wherein said PUFA is covalently bound to said glycerophospholipid. The preparation possesses an improved bioactivity, and is useful in the treatment of various cognitive and mental conditions and disorders and for maintenance of normal functions of brain-related systems and processes.

Abstract: In its many embodiments, the present invention relates to a novel class of substituted azepine- and diazepine-sulfonamide compounds useful to inhibit 11?-hydroxysteroid dehydrogenase type-I, pharmaceutical compositions containing the compounds, and methods of treatment, prevention, inhibition, or amelioration of one or more conditions associated with the expression of 11?-hydroxysteroid dehydrogenase type-I using such compounds or pharmaceutical compositions.

Abstract: The present invention relates to a powdered chewing gum composition, which contains over 50% w/w chewing gum base and wherein at least 95% w/w of the particles of the composition have a particle size of less than 1200 micron in diameter. The present invention also relates to the use of said powdered chewing gum composition. The present invention also relates to a chewing gum comprising a) a core component, and b) one or more layers comprising the composition of the present invention. The present invention further relates to a method for production of said chewing gum comprising the steps of: (a) providing a core composition; and (b) coating of the core composition with a powdered chewing gum composition by use of a panning process; and optionally (c) coating the outer intermediate layer with an outer finishing layer by use of a panning process.

Abstract: The disclosed subject matter, in one aspect, relates to compounds and compositions {e.g., polysaccharides and polysaccharide complexes) and methods for providing and using such compounds and compositions. Disclosed are compositions comprising a polysaccharide or polysaccharide complex obtained from Chlorella, wherein the polysaccharide or polysaccharide complex has a molecular weight of from about 1×103 to about 1×106 Da. Also disclosed are methods of providing a polysaccharide or polysaccharide complex, comprising the steps of providing a Chlorella extract, contacting the extract with a solvent to provide a precipitate, contacting the precipitate with additional substances {e.g., a surfactant) and isolating an insoluble fraction, and size fractioning the insoluble fraction, thereby providing the polysaccharide or polysaccharide complex. Disclosed are also methods for using the disclosed polysaccharide and polysaccharide compositions.

Abstract: The present invention is directed to a dried seamless capsule comprising an alginate shell membrane encapsulating fill material, wherein: (i) said alginate shell membrane comprises a polyvalent metal ion alginate having: (a) an average M content of from 50%-62% by weight based on the weight of the M and G content, and (b) a viscosity of 35 to 80 cps when measured as a monovalent metal ion alginate in a 3.5% water solution at 20° C. using a Brookfield LV viscometer at 60 rpm and spindle #1; (ii) said alginate shell membrane encapsulates an oil present in an amount of at least 50% by weight of said fill material; (iii) said dried seamless capsule has a disintegration time of less than 12 minutes in an intestinal buffer after pretreatment for 20 minutes in a solution of 0.1 M NaCl and HCl, pH of 3, at 37° C.; and (iv) said dried seamless capsule has a dry break force strength of at least 7 kg. The present invention is also directed to methods of making and using such dried seamless capsules.

Abstract: The present invention relates to the use of isosteviol, steviol, and related compounds for elevating the plasma HDL-cholesterol level. The invention furthermore relates to the use of these compounds for reducing the body weight of a subject and/or lowering the plasma triglyceride level of a subject, including a concomitant elevation of the plasma HDL-cholesterol level. Preferably the compounds used are isosteviol and/or steviol, or pharmaceutically acceptable salts, solvates or prodrugs thereof. The compounds may furthermore be administered in combination with one or more further active compounds, such as e.g. LDL-cholesterol lowering agents. The invention furthermore relates to a method for elevating the plasma HDL-cholesterol level in a subject by administering to a subject in need of such treatment a plasma HDL-cholesterol level elevating amount of the compounds, described herein.

Abstract: Milkweed seed oil administered to an animal improves the health of the animal. This improvement is evidenced by the positive change in the analytical results of blood tests for cholesterol after the animal has been administered an effective amount of milkweed seed oil as compared to the blood test results of the animal before the milkweed seed oil was administered.

Abstract: Several diterpene glycosides (e.g., rubusoside, rebaudioside, steviol monoside and stevioside) were discovered to enhance the solubility of a number of pharmaceutically and medicinally important compounds, including but not limited to, paclitaxel, camptothecin, curcumin, tanshinone HA, capsaicin, cyclosporine, erythromycin, nystatin, itraconazole, and celecoxib. The use of the diterpene glycoside rubusoside increased solubility in all tested compounds. The diterpene glycosides are a naturally occurring class of water solubility-enhancing compounds that are non-toxic and that will be useful as new complexing agents or excipients in the pharmaceutical, agricultural (e.g., solubilizing pesticides), cosmetic and food industries. Aqueous solutions by using rubusoside to increase the solubility of otherwise insoluble drugs will have several new routes of administration. In addition, aqueous solutions of therapeutic compounds with rubusoside were shown to retain the known pharmacological activity of the compounds.

Abstract: A cosmetic or pharmaceutical composition, to be applied topically is described, which has a hydrophilic outer phase, at least one cosmetic and/or pharmaceutical active ingredient and at least one carrier substance for the active ingredient. The carrier substance here forms such structures, which comprises at least two lamellar double membrane layers arranged one over another in the manner of a sandwich, wherein between adjacent double membrane layers, aligned parallel to each other, a layer of an inner phase is respectively arranged.

Abstract: The invention provides a method for preparing microparticles comprising mixing a first cross-linkable reagent in aerosol form with a second cross-linking reagent in aerosol form to thereby to form microparticles.

Abstract: The present subject matter relates to a novel herbal and oil composition and methods for modulating fatty acid composition and metabolism in an animal. In one aspect, the subject matter involves a composition comprising rosemary extract, oregano extract, and a polyunsaturated oil. In a particular embodiment, the polyunsaturated oil is fish oil or a derivative thereof. In some embodiments, the present subject matter relates to methods for modulating essential dietary fatty acid composition of lipoprotein particles or cell membranes, modulating essential fatty acid metabolism, regulating the activity of lipoxygenases and cyclooxygenases, improving cardiovascular health, and/or inhibiting cell proliferation diseases and disorders.

Abstract: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Abstract: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Abstract: The invention relates to methods and compositions for treating and preventing pulmonary hemorrhage in an animal, and for reducing red blood cells in the airways of an animal. More particularly, the invention relates to methods and compositions for treating and preventing pulmonary hemorrhage in an animal, and for reducing red blood cells in the airways of an animal wherein a feed composition comprising an about 3:1 to an about 1:3 ratio of docosahexaneoic acid to eicosapentaenoic acid is fed to the animal.

Abstract: Nanoparticulate compositions comprising at least one poorly soluble angiogenesis inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

Abstract: A composition and method of using a composition containing kunzea oil for treating dermatological conditions in humans and animals, particularly greasy heel occurring in horses, in which the kunzea oil is formulated into a composition for topical application at ambient temperatures to the skin of the animal or human to cover the area of the affected lesions. Improvement in certain dermatological conditions such as pastern dermatitis in horses was noted almost immediately with total resolution of the condition in about 7 days. The composition can be used to treat humans suffering from psoriasis and similar dermatological conditions. This invention offers persons and animals suffering from dermatological conditions a low cost effective treatment based on a natural product which shows significant improvement of the condition within days of applying an effective amount of the composition to the affected area as part of the treatment.

Abstract: The present invention refers to pharmaceutical formulations based on lipids for ophthalmic use comprising a phospholipid component composed of zwitterionic phospholipids of natural origin and an oily component composed of oils of natural origin emulsified in water. In particular, the invention refers to ophthalmic formulations useful, for example, for transporting drugs to the eye and in the treatment of ocular dryness, capable of restoring the lipid layer of the tear film. In particular, in a non-transitory but pathological situation such as the dry eye syndrome, such formulations also succeed in reducing the often-present inflammatory component.

Abstract: Gene expression patterns were analyzed that identified multiple genes associated with radiation enhanced colon carcinogenesis. Some of the genes modulated by radiation exposure may be involved in up-regulating the Wnt/?-catenin signaling pathway and promote colon carcinogenesis. Consumption of a fish oil/pectin diet caused a general down-regulation of genes encoding proteins involved in cell adhesion and receptor activity, which may be involved in down-regulating the Wnt/?-catenin signaling pathway. The data suggest that dietary fish oil/pectin may be an effective countermeasure against radiation-induced colon carcinogenesis. In accordance with this, gene expression profiles can be monitored to reduce the risk of radiation induced carcinogenesis in high risk personnel (i.e., for example, astronauts) before, during, and/or after radiation exposure (i.e., for example, spaceflight), and/or to detect radiation-induced carcinogenesis so that an appropriate countermeasure administration can be implemented.

Abstract: The invention relates to a process for decreasing the amount of environmental pollutants in a mixture comprising a fat or an oil, being edible or for use in cosmetics, the fat or oil containing the environmental pollutants, which process comprises the steps of adding a volatile working fluid to the mixture, where the volatile working fluid comprises at least one of a fatty acid ester, a fatty acid amide, a free fatty acid and a hydro-carbon, and subjecting the mixture with the added volatile working fluid to at least one stripping processing step, in which an amount of environmental pollutant present in the fat or oil, being edible or for use in cosmetics, is separated from the mixture together with the volatile working fluid. The present invention also relates to a volatile environmental pollutants decreasing working fluid, for use in decreasing an amount of environmental pollutants present in a fat or oil, being edible or for use in cosmetics.

Abstract: A composition is provided which includes an enriched fish oil as a lipid source. Also provided is a composition which includes a fatty acid of a fish oil and a medium-chain triglyceride, wherein the composition is an oil-in-water emulsion.

Abstract: This invention concerns a composition for regulating lipid metabolism and methods that may be used in the food industry as well as in the nutraceutical and therapeutic fields. In particular, the invention involves food additives or supplements, a composition containing these and the use thereof, in particular for revitalizing a subject's metabolism, in particular, that of human beings.

Abstract: The present invention relates to nutritional or pharmaceutical compositions comprising lactoferrin and glycine with an anti-inflammatory activity suitable for patients with an inflammatory disease.

Abstract: The present invention is directed to transdermal compositions and the uses thereof. These compositions include at least one of the following components: a C1-C6 dialkyl, C12-C30 dialkyl quaternary ammonium salt, a C12-C30 fatty acid, a nitrogenous organic base, C12-30 fatty alcohol, monoglyceride or the reaction products thereof.

Abstract: The present invention comprises a composition with means to inhibit the function of the inflammatory cytokine IL-1 and methods for using this composition to treat inflammatory disease of ocular and adnexal tissues by topical administration. The present invention also discloses devices for delivering this composition to target tissues.

Abstract: Methods of using absorption enhancer as a component of skin care compositions for moisturizing and protecting the skin. Antimicrobial skin care compositions for cleansing and moisturizing the skin, comprising an absorption enhancer, an antimicrobial function enhancer and bound lipid removals, humectants, emollients and extracts of botanical herbs. Methods for preparing skin care compositions comprising an absorption enhancer.

Abstract: An animal feed supplement includes fish meal as a source of omega 3 long chain fatty acids for inclusion in the diet of an animal. The animal feed supplement also includes at least one naturally-occurring antioxidant; at least one synthetic antioxidant; an antibacterial agent; an anti-mold/anti-fungal agent; and an anti-chemical activity agent. The omega 3 long chain fatty acids are provided at a level which maximizes the nutritional value of food produce from the animal, but without taint of the food produce. The feed supplement is greater than 5% of the total dietary intake of the animal.

Abstract: There are provided various compounds and compositions comprising polyunsaturated fatty acid monoglycerides and derivatives thereof. These compounds and compositions can be useful as cancer chemopreventive agents. They can also be useful for enhancing solubility of various active agents and enhancing their bioavailability.

Abstract: The present invention relates to methods for assessing an individual's susceptibility to treatment of an inflammatory disease with a dietary supplement. The invention describes the recognition that the sensitivity of an individual to the inflammation suppressing effects of fish oil on TNF-a production is linked both to genetic variation encoded by, or associated with, TNF-a and/or IL-6 single nucleotide polymorphisms and to the inherent level of production of TNF-a by cells.

Abstract: The present invention concerns the use of an oil-in-water emulsion where the interior of oil droplets exhibit interfaces, between lipophilic domains and hydrophilic or amphiphilic domains, due to the presence of a lipophilic additive solubilized inside the oil droplets and which is used for delayed release of active elements such that the release of at least one active element, which has a octanol/water partitioning coefficient logP higher than ?1, corresponds to a higher Tmax than the Tmax obtained for the simple reference oil-in-water emulsion where no lipophilic additive is used.

Abstract: Gastric resistant film-forming compositions are described herein. The composition comprises a gastric resistant natural polymer, a film-forming natural polymer, and optionally a gelling agent. Suitable gastric resistant natural polymers include polysaccharides such as pectin and pectin-like polymers. The film-forming composition can be used to prepare soft or hard shell gelatin capsules which can encapsulate a liquid or semi-solid fill material or a solid tablet (Softlet®) comprising an active agent and one or more pharmaceutically acceptable excipients. Alternatively, the composition can be administered as a liquid with an active agent dissolved or dispersed in the composition. The compositions are not only gastric resistant but may also prevent gastric reflux associated with odor causing liquids, such as fish oil or garlic oil, encapsulated in a unit dosage form and esophageal irritation due to the reflux of irritant drugs delivered orally.

Abstract: The invention relates to a process for the preparation of deodorized and stabilized food-grade marine oils by submitting marine oils to a counter-current steam distillation (CCSD) in a thin film column containing a structured packing and, if desired, adding antioxidant(s), to the food-grade marine oils thus obtained and to their uses in the food/feed, cosmetic and/or pharmaceutical industry.